T-1101 capsule approved by the FDA to start Phase I clinical study
Taivex received US FDA Investigational New Drug Application (IND) Approval for T-1101 capsule on Nov. 2021, to initiate phase I clinical trial. T-1101: T-1101 acts through disrupting the interaction between Hec1 and Nek2 to leads to tumor cells apoptosis. T-1101 demonstrated potent anti-cancer activity in different mouse xenograft models of human cancers, including liver and …
T-1101 capsule approved by the FDA to start Phase I clinical study Read More »